Anne Rabbitte (Fianna Fail)

I really welcome Professor Barry's answer on that. I want to go another step. If we do not change the way we are doing, it the assessment process for patients will continue to face delays in getting potentially life-changing treatments. Is it possible to establish an early access programme for rare disease treatments to allow patients with little or no options to avail of treatments early while still assessing them for reimbursement? I am thinking of selumetinib.